Glenmark Gets Early Win In Challenge To Merck's Zetia Patent Claims
This article was originally published in PharmAsia News
India's Glenmark Phrmaceuticals has won a favorable decision in a U.S. court against Merck and its patents on Zetia (ezetimibe) for controlling cholesterol
You may also be interested in...
Risk, Reward Sharing Extends To Generics: Glenmark, Par Tango As Lanuch Prospects For Zetia Copies Brighten
MUMBAI - Its raining deals for the Indian drug maker Glenmark. A day after the $450 million generics-cum-innovation driven pharma signed an out-licensing agreement with Sanofi Aventis for a novel research compound in pain management, it has now announced another one-of-its-kind licensing agreement - this time with Par Pharma to market generic versions of Merck/Schering Plough's $1.4 billion cholesterol drug Zetia (ezetimibe) in the United States
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.